Objectives

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract that commonly result in iron deficiency anemia (IDA) due to impaired iron absorption and chronic blood loss. Patients with IBD experience reduced health-related quality of life, with fatigue playing a key role. The aim of the present analysis was to calculate health state utility values (HSUVs) from a recent randomized controlled trial (RCT) of intravenous iron in the treatment of patients with IBD and IDA.

Methods

SF-6Dv2 HSUVs were derived from responses to the SF-36v2 from patients enrolled in PHOSPHARE-IBD, a double-blinded RCT comparing equivalent dosing regimens of ferric derisomaltose (FDI) versus ferric carboxymaltose (FCM) in the treatment of IDA in patients (N=97) with IBD. Country-specific utility weights from the United Kingdom were used to derive the SF-6Dv2 HSUVs, and a mixed model analysis was conducted of HSUVs over time.

Results

In the FDI arm, HSUVs increased significantly from baseline by a maximum of 0.25 points (p=0.0001) at day 49 and 0.20 points (p=0.0021) at end-of-trial (day 70). In the FCM arm, the HSUVs increased by 0.12 points at day 49 to a maximum of 0.13 at day 70, but the changes were not significant (p=0.078 and p=0.056, respectively). The mixed model analysis showed HSUVs were 0.13 and 0.07 points higher in the FDI arm at day 49 and 70, respectively, although a comparison over all follow-up time points showed that the difference between the two treatment arms was not significant (p=0.058).

Discussion

The present analysis showed improvements in HSUVs after administration of FDI and FCM in patients with IBD and IDA, with larger and significant improvements after administration of FDI. These HSUVs can inform future cost utility analysis and treatment decisions by clinicians as well as health care payers.